Science
CYT997 possesses potent vascular disrupting properties against tumor blood vessels. Studies in several cancer models have demonstrated that the compound ablates the blood vessels which serve growing tumors whilst sparing normal, healthy blood vessels. By attacking tumor vessels, the compound can lead to tumor blood flow arrest, starvation of rapidly dividing tumor cells and tumor death. The compound also directly affects tumor cell replication via its inhibition of the cellular structural protein, tubulin.
Manuscripts
|
|
Monaghan K, et al. CYT997 causes apoptosis in human multiple myeloma. Invest New Drugs 2009 Nov 12 [Epub ahead of print] |
|
|
Burns CJ, et al. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther 2009 Nov; 8: 3036-3045 |
|
|
Daenen LG, et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009 Oct; 8: 2872-2881 |
|
|
Burns CJ, et al. Discovery of CYT997: a structurally novel orally active microtubule targeting agent. Bioorg Med Chem Lett 2009 Aug 15; 19(16): 4639-4642 |
Posters and Abstracts